Gene therapy for atherosclerotic cardiovascular disease: A time for optimism and caution

Timothy O'Brien, Robert D. Simari

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Cardiovascular disease is the leading cause of death in the Western world, and gene therapy approaches to several cardiovascular disorders have been proposed. One of the major stumbling blocks to be overcome before widespread clinical use of this technology is how to deliver DNA efficiently and safely to cells in vivo. While delivery of DNA alone is inefficient, use of viral vectors may overcome this problem. Adenoviral vectors are most commonly used in cardiovascular gene delivery, but toxicity related to these vectors remains a concern. In addition, duration of gene expression with use of these vectors is limited, which may be advantageous in settings in which transient expression is satisfactory to obtain a therapeutic effect. Gene therapy has been suggested as an approach to multiple conditions, including restenosis after angioplasty, therapeutic neovascularization, and bypass graft restenosis. Phase 1 clinical trials were recently reported. While proof of principle has been established in preclinical animal models, convincing efficacy data in humans do not yet exist. Improvements in vector technology and methods of catheter-mediated vascular gene delivery are needed before widespread clinical application of this therapy.

Original languageEnglish (US)
Pages (from-to)831-834
Number of pages4
JournalMayo Clinic Proceedings
Volume75
Issue number8
StatePublished - 2000

Fingerprint

Genetic Therapy
Cardiovascular Diseases
Technology
Vascular Access Devices
Western World
Clinical Trials, Phase I
DNA
Therapeutic Uses
Angioplasty
Genes
Cause of Death
Animal Models
Transplants
Gene Expression
Therapeutics
Optimism

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Gene therapy for atherosclerotic cardiovascular disease : A time for optimism and caution. / O'Brien, Timothy; Simari, Robert D.

In: Mayo Clinic Proceedings, Vol. 75, No. 8, 2000, p. 831-834.

Research output: Contribution to journalArticle

O'Brien, Timothy ; Simari, Robert D. / Gene therapy for atherosclerotic cardiovascular disease : A time for optimism and caution. In: Mayo Clinic Proceedings. 2000 ; Vol. 75, No. 8. pp. 831-834.
@article{6aa63da38897496dad178a57d0e1e855,
title = "Gene therapy for atherosclerotic cardiovascular disease: A time for optimism and caution",
abstract = "Cardiovascular disease is the leading cause of death in the Western world, and gene therapy approaches to several cardiovascular disorders have been proposed. One of the major stumbling blocks to be overcome before widespread clinical use of this technology is how to deliver DNA efficiently and safely to cells in vivo. While delivery of DNA alone is inefficient, use of viral vectors may overcome this problem. Adenoviral vectors are most commonly used in cardiovascular gene delivery, but toxicity related to these vectors remains a concern. In addition, duration of gene expression with use of these vectors is limited, which may be advantageous in settings in which transient expression is satisfactory to obtain a therapeutic effect. Gene therapy has been suggested as an approach to multiple conditions, including restenosis after angioplasty, therapeutic neovascularization, and bypass graft restenosis. Phase 1 clinical trials were recently reported. While proof of principle has been established in preclinical animal models, convincing efficacy data in humans do not yet exist. Improvements in vector technology and methods of catheter-mediated vascular gene delivery are needed before widespread clinical application of this therapy.",
author = "Timothy O'Brien and Simari, {Robert D.}",
year = "2000",
language = "English (US)",
volume = "75",
pages = "831--834",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "8",

}

TY - JOUR

T1 - Gene therapy for atherosclerotic cardiovascular disease

T2 - A time for optimism and caution

AU - O'Brien, Timothy

AU - Simari, Robert D.

PY - 2000

Y1 - 2000

N2 - Cardiovascular disease is the leading cause of death in the Western world, and gene therapy approaches to several cardiovascular disorders have been proposed. One of the major stumbling blocks to be overcome before widespread clinical use of this technology is how to deliver DNA efficiently and safely to cells in vivo. While delivery of DNA alone is inefficient, use of viral vectors may overcome this problem. Adenoviral vectors are most commonly used in cardiovascular gene delivery, but toxicity related to these vectors remains a concern. In addition, duration of gene expression with use of these vectors is limited, which may be advantageous in settings in which transient expression is satisfactory to obtain a therapeutic effect. Gene therapy has been suggested as an approach to multiple conditions, including restenosis after angioplasty, therapeutic neovascularization, and bypass graft restenosis. Phase 1 clinical trials were recently reported. While proof of principle has been established in preclinical animal models, convincing efficacy data in humans do not yet exist. Improvements in vector technology and methods of catheter-mediated vascular gene delivery are needed before widespread clinical application of this therapy.

AB - Cardiovascular disease is the leading cause of death in the Western world, and gene therapy approaches to several cardiovascular disorders have been proposed. One of the major stumbling blocks to be overcome before widespread clinical use of this technology is how to deliver DNA efficiently and safely to cells in vivo. While delivery of DNA alone is inefficient, use of viral vectors may overcome this problem. Adenoviral vectors are most commonly used in cardiovascular gene delivery, but toxicity related to these vectors remains a concern. In addition, duration of gene expression with use of these vectors is limited, which may be advantageous in settings in which transient expression is satisfactory to obtain a therapeutic effect. Gene therapy has been suggested as an approach to multiple conditions, including restenosis after angioplasty, therapeutic neovascularization, and bypass graft restenosis. Phase 1 clinical trials were recently reported. While proof of principle has been established in preclinical animal models, convincing efficacy data in humans do not yet exist. Improvements in vector technology and methods of catheter-mediated vascular gene delivery are needed before widespread clinical application of this therapy.

UR - http://www.scopus.com/inward/record.url?scp=0033889261&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033889261&partnerID=8YFLogxK

M3 - Article

C2 - 10943238

AN - SCOPUS:0033889261

VL - 75

SP - 831

EP - 834

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 8

ER -